A second drug in the new class of medications known as PCSK9 inhibitors has been approved for use in patients who can’t adequately reduce their low-density lipoprotein (LDL) cholesterol level with current treatments.
Evolocumab, marketed as Repatha, is approved for use with diet and maximally tolerated statin therapy in adults with heterozygous familiar hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease such as myocardial infarction or stroke who need to lower their LDL cholesterol (http://1.usa.gov/1KRg3o6).
Voelker R. Another Option to Lower LDL. JAMA. 2015;314(13):1332. doi:10.1001/jama.2015.12087